Friday, November 20, 2026·Focal News

The San Francisco Focal

San Francisco's independent voice

Local

San Francisco Launches $500K Pilot to Offer Same-Day Buprenorphine Injections for Fentanyl Addiction

A new city-funded pilot at the Maria X Martinez Health Resource Center lets clinicians administer long-acting buprenorphine injections on demand, removing a major barrier for people seeking treatment for fentanyl addiction. The program aims to reach 460 starting doses over two years and could expand to five more clinics by 2027.

San Francisco Launches $500K Pilot to Offer Same-Day Buprenorphine Injections for Fentanyl Addiction

San Francisco has launched a $500,000 pilot program to make it easier for people addicted to fentanyl to start treatment immediately, by offering long-acting buprenorphine injections on demand at a city clinic in SoMa.

The program, which began Nov. 2 at the Maria X Martinez Health Resource Center, allows clinicians to stock and administer the injections onsite for the first time. Previously, patients seeking the treatment had to be referred elsewhere, a detour that often meant losing the brief window when someone is ready to begin recovery.

Buprenorphine is an opioid medication that partially activates the same brain receptors as fentanyl, reducing cravings and withdrawal symptoms without producing a high. Both buprenorphine and methadone cut the risk of overdose death by about 50 percent, according to Dr. Sarah Rosenwohl-Mack, an addiction specialist at UCSF who advised the city on the pilot’s planning and dosing protocols.

The newer injectable formulations offer a critical advantage over tablets: patients can receive their first injection while still using fentanyl, without having to endure withdrawal first. That is a significant shift, because starting conventional buprenorphine too soon after fentanyl use can trigger precipitated withdrawal—a sudden, severe worsening of symptoms that patients describe as agonizing.

“That’s the real innovation of the injections,” Rosenwohl-Mack said. “It’s a way to start treatment that is much more possible for our patients.”

The Martinez clinic, a walk-in facility that sees about 21,000 patient visits a year, serves a population where more than three-quarters of clients experience homelessness. Dr. Tanya Majumder, the clinic’s medical director, said patients’ willingness to start treatment can be fleeting—sometimes lasting only half an hour.

“Having the medication on hand means we can act immediately when a patient expresses readiness to stop using fentanyl,” Majumder said. The injections also eliminate the need to take daily medication or safeguard pills, which is especially difficult for people without stable housing.

The pilot is budgeted for 460 starting doses and 500 follow-up doses over two years. The city plans to track treatment retention, overdoses, emergency department visits and hospitalizations through April 2028, with the goal of expanding injectable buprenorphine to as many as five additional clinics in 2027. The program is funded largely through Breaking the Cycle, a public-private fund launched by Mayor Daniel Lurie to support homelessness and behavioral health initiatives.

Rosenwohl-Mack led a 2025 study of 131 cases in which patients started treatment with buprenorphine injections at safety-net clinics in San Francisco and Oakland. It found that 43 percent remained on buprenorphine three months later—a result she called encouraging given the housing instability many patients face.

A 2018 randomized trial of 428 patients at U.S. outpatient clinics found that weekly and monthly injections were at least as effective as daily medication at reducing illicit opioid use and keeping patients in treatment. A 2024 follow-up analysis suggested extended-release injections may offer an advantage in reducing fentanyl use specifically.

Dr. Gail D’Onofrio, a Yale University emergency medicine professor who studies addiction, emphasized the need for multiple treatment pathways. “There isn’t ‘one size fits all,’” she said.

Rosenwohl-Mack said same-day access to buprenorphine injections remains rare nationally, and she praised San Francisco’s expansion as “phenomenal.” She recalled a patient she treated in 2024—a man in his 40s who had used fentanyl daily for years and had not succeeded with other treatments. After his first injection, he told her it was the “smoothest” experience he’d ever had starting buprenorphine. He remains on the medication today.

“‘Oh my God, my friend was totally right,’” Rosenwohl-Mack recalled him saying. “‘I’m going to go tell everyone else.’”

More from The San Francisco Focal